Y2 Solution's Bio Business create the value through open innovation strategy which is securing the early-stage original technology from global leading research institution or colleges and license out the proven technology through clinical trial.
Since launching Bio Business in 2018, we have established joint venture, Luxa Biotechnology LLC, together with Neural Stem Cell Institute, to develop dry-AMD(age-related macular degeneration) treatment. Luxa Biotechnology conducts clinical trial in the States.
We sincerely hope that our treatment not only enhance the value of the company, but ultimately gives hope to patients suffering from the disease.